Noema Pharma extends its series B funding to $147M, advancing phase 2 trials for CNS disorders like Tourette syndrome, ...

Most drug discovery efforts aimed at type 2 diabetes target insulin action in peripheral tissues (muscle, fat and liver). Recently, data have emerged that suggest the central nervous system (CNS ...

If the latest neurosteroid fails against Huntington's, it's going lower than that and the company's future is very much in doubt. Central nervous system drug development is definitely for the brave.

In the case of drugs developed for central nervous system (CNS) conditions such as Alzheimer disease and Parkinson disease, getting through the blood–brain barrier (BBB) is a major hurdle.

A broad range of nanomedicines is being developed to improve drug delivery for CNS disorders. The structure of the blood-brain barrier (BBB), the presence of efflux pumps and the expression of ...

The various regional players operating in CNS therapeutics market adopt acquiring government funding to support novel ...

This not only makes eradication of the virus very difficult but also increases the risk of viral mutation, leading to drug resistance and treatment failure. One of these sites is the CNS.

The two companies will work together on the development of a “next-generation” of psychiatric medicines, although – for now – the drugs themselves and the target indications are being kept ...

Under the terms of the deal, Autifony will lead drug discovery and preclinical development ... “exceptional track record” of bringing new CNS therapies to market, alluding to the company ...

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today ...

Minoryx Therapeutics plans to submit European approval for leriglitazone after Phase II NEXUS trial shows 35% disease arrest ...